Dyspnea Market Report and Forecast 2025-2034

The global dyspnea market attained a value of USD 6.50 Billion in 2024. The market is further expected to grow in the forecast period of 2025-2034 at a CAGR of 6.90%, to reach USD 12.67 Billion by 2034.

Dyspnea Market Overview

Dyspnea involves breathlessness or breathing discomfort characterized by distinct sensations that vary in intensity. It may occur due to heavy physical exertion, or as a side effect of asthma, cardiac ischemia, pneumonia, and congestive heart failure, among others. Dyspnea has become more common after COVID-19, as the virus primarily attacked the lungs of patients. As per a study conducted in 76 patients, clinical meaningful dyspnea affected 49% of the patients at 3 months, while 24% of the patients experienced the symptoms getting worse between 3-12 after COVID-19 exposure.

The dyspnea market growth is driven by the advent of targeted therapies modes, aimed to offer effective treatment. The market is experiencing a surge in research and development activities for the development of new drugs and therapies. The increasing prevalence of respiratory disorders such as asthma, pneumonia, myocardial ischemia, and other respiratory disorders globally is a major factor contributing to the market share. The market is further expected to be driven by the rising prevalence of indoor as well as outdoor pollution. The rising expenditure on the development of healthcare infrastructure is another major factor bolstering the market value.

FDA Approvals to Develop Effective Treatment Alternative to Patients

The market is expected to experience significant growth driven by the increased prevalence of respiratory disorders such as asthma. To meet the dyspnea market demand, there has been a surge in new drug developments and their FDA approvals. For instance, in January 2023, the U.S. FDA approved Airsupra, an inhalational aerosol to treat asthma in adults (18 or older). Administered as a combination of albuterol and budesonide, it is the foremost combination of an inhaled corticosteroid and short-acting beta-agonist. The increasing incidence of FDA approvals is expected to fill a crucial gap of unmet needs in asthma treatment. In addition, increasing drug approvals are also expected to spark competition among key players, bolstering the market growth in the forecast period.

Surge in Investments to Drive Market Growth

The increased initiatives from the government to spread awareness about respiratory disorders and to get diagnosed in time for appropriate treatment are some of the significant dyspnea market trends. Moreover, an increasing number of funding activities to fetch treatments for asthma and other respiratory are collectively influencing market growth. For instance, in October 2023, San Francisco and London-based Aiolos Bio (a new startup with an asthma drug in clinical trials) declared that it raised USD 245 million in Series A funding. Such fundings support the development of drugs for clinical treatment, leading to expansion of the market.

Dyspnea Market Segmentations

Dyspnea Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Treatment Type

• Supplemental Oxygen Therapy
• Relaxation Therapy

Market Breakup by Drug Class

• Antianxiety
• Antibiotics
• Anticholinergic Agents
• Corticosteroids
• Others

Market Breakup by Route of Administration

• Oral
• Inhalation
• Others

Market Breakup by End User

• Hospitals
• Homecare
• Specialty Clinics
• Ambulatory Services
• Others

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan
• China

Dyspnea Market Regional Analysis

North America is leading the regional market, driven by the presence of advanced treatments and the availability of distribution channels to access appropriate drugs for treatment. The presence of a robust healthcare system is a major factor attributing to the growth of the region. In November 2023, Dupixent® (dupilumab), Sanofi’s investigational drug for treating COPD showed positive results in the Phase 3 BOREAS trial. The drug reduced COPD exacerbations by 34%. As a part of the results, it was also revealed that the drug offered improvement in lung function by 12 weeks, and it was sustained at 52 weeks. The existence of prominent healthcare companies attribute to the dyspnea market share in the region.

Europe, having several research and academic institutions holds a significant market share. In addition, a huge geriatric population base is expected to increase the demand for dyspnea treatment in the forecast period.

Asia Pacific is poised to witness significant growth, owing to rising investments in improving the medical infrastructure. There has been substantial development and prevalence for alternative therapies to treat the condition in patients. The amalgamation of traditional medicine with novel techniques is anticipated to drive the dyspnea market size in the region.

Dyspnea Market: Competitor Landscape

In July 2023, Lupin Limited, revealed that its Australian subsidiary, Generic Health Pty Ltd, received approval for Tiotropium 18 micrograms powder for inhalation from Therapeutic Goods Administration (TGA). The approved drug can be used in combination with Lupin Haler and is indicated treating long-term bronchospasm along with dyspnea associated with chronic obstructive pulmonary disease (COPD). It has also been found effective in preventing COPD exacerbations. The surge in drug approvals from key regulatory authorities has been a major market trend, expected to boost the market size in the forecast period.

The key features of the dyspnea market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Bausch Health
• GlaxoSmithKline plc
• Teva Pharmaceutical Industries Ltd
• Ligand Pharmaceuticals Incorporated
• Amneal Pharmaceuticals LLC
• Jazz Pharmaceuticals, Inc
• Mylan N.V
• Lupin
• Pfizer Inc
• Novartis AG
• Boehringer Ingelheim International GmbH
• Sun Pharmaceutical Industries Ltd
• Aurobindo Pharma
• Nephron Pharmaceuticals Corporation
• Zydus Cadila

Please note that this only represents a partial list of companies, and the complete list has been provided in the report.

This product will be delivered within 3-5 business days.